Trial · NCT07912970
Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours
NCT07912970, Phase 3, Not yet recruiting, Fujian Medical University Union Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours. Trials, record NCT07912970. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912970
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours
- NCT number
- NCT07912970
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 1,266 participants, estimated
- Lead sponsor
- Fujian Medical University Union Hospital
- Conditions
- Acute Ischemic Stroke, Large Vessel Occlusion
- Interventions
- Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Functional Independence at 90 Days | Day 90 ± 7 days after randomization | Proportion of participants with functional independence at 90 days after randomization, defined as a modified Rankin Scale score of 0 to 2. The modified Rankin Scale ranges from 0 to 6, with lower scores indicating less disability. |
| Secondary | Distribution of Modified Rankin Scale Scores at 90 Days | Day 90 ± 7 days after randomization | Distribution of modified Rankin Scale scores at 90 days after randomization. The modified Rankin Scale ranges from 0 to 6, with higher scores indicating greater disability. |
| Secondary | Excellent Functional Outcome at 90 Days | Day 90 ± 7 days after randomization | Proportion of participants with a modified Rankin Scale score of 0 to 1 at 90 days after randomization. |
| Secondary | Favorable Functional Outcome at 90 Days | Day 90 ± 7 days after randomization | Proportion of participants with a modified Rankin Scale score of 0 to 3 at 90 days after randomization. |
| Secondary | Early Recanalization of the Target Vessel at the Receiving Stroke Center | Within 24 hours after randomization (at the first vascular imaging assessment upon arrival at the receiving stroke center). | Proportion of participants with recanalization of the initially occluded target vessel on the first vascular imaging assessment at the receiving stroke center, assessed by CTA, MRA, or the first DSA. |
| Secondary | Successful Recanalization of the Target Vessel Within 48 Hours | Within 48 hours after randomization | Proportion of participants with recanalization of the initially occluded target vessel on CTA or MRA within 48 hours after randomization. |
| Secondary | Early Neurological Improvement | 72 ± 12 hours after randomization | Proportion of participants with a decrease in the National Institutes of Health Stroke Scale (NIHSS) score of at least 8 points from baseline, or an NIHSS score of 0 to 1, at the 72-hour assessment. |
| Secondary | EQ-5D-5L Score at 90 Days | Day 90 ± 7 days after randomization | EQ-5D-5L assessment at 90 days after randomization, performed by an assessor blinded to treatment allocation. |
| Secondary | Barthel Index at 90 Days | Day 90 ± 7 days after randomization | Barthel Index score at 90 days after randomization, assessed by an assessor blinded to treatment allocation. Scores range from 0 to 100, with higher scores indicating greater independence in activities of daily living. |
| Other | Symptomatic Intracranial Hemorrhage Within 48 Hours | Within 48 hours after randomization | Proportion of participants with symptomatic intracranial hemorrhage within 48 hours after randomization, adjudicated according to the Heidelberg Bleeding Classification. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912970
GET https://conductscience.org/api/trials/v1/NCT07912970/registered